Benzodiazepine use and neuroimaging markers of Alzheimer's disease in nondemented older individuals: an MRI and 18F Florbetapir PET study in the MEMENTO cohort.
Journal
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
02
07
2021
accepted:
19
11
2021
revised:
15
11
2021
pubmed:
12
12
2021
medline:
13
4
2022
entrez:
11
12
2021
Statut:
ppublish
Résumé
Recent evidence suggests an association between benzodiazepines (BZDs) use and lower brain amyloid load, a hallmark of AD pathophysiology. Other AD-related markers include hippocampal atrophy, but the effect of BZDs on hippocampal volume remains unclear. We aimed at 1) replicating findings on BZDs use and brain amyloid load and 2) investigating associations between BZDs use and hippocampal volume, in the MEMENTO clinical cohort of nondemented older adults with isolated memory complaint or light cognitive impairment at baseline. Total Standardized Uptake Value Ratio (SUVR) of brain amyloid load and hippocampal volume (HV) were obtained, respectively, from
Identifiants
pubmed: 34893757
doi: 10.1038/s41386-021-01246-5
pii: 10.1038/s41386-021-01246-5
pmc: PMC8938511
doi:
Substances chimiques
Amyloid beta-Peptides
0
Aniline Compounds
0
Biomarkers
0
Ethylene Glycols
0
Benzodiazepines
12794-10-4
florbetapir
6867Q6IKOD
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1114-1120Subventions
Organisme : Medical Research Council
ID : MR/T033371/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L023784/2
Pays : United Kingdom
Informations de copyright
© 2021. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.
Références
Islam MM, Iqbal U, Walther B, Atique S, Dubey NK, Nguyen PA, et al. Benzodiazepine use and risk of dementia in the elderly population: a systematic review and meta-analysis. Neuroepidemiology. 2016;47:181–91.
doi: 10.1159/000454881
Tseng L-Y, Huang S-T, Peng L-N, Chen L-K, Hsiao F-Y. Benzodiazepines, z-hypnotics, and risk of dementia: special considerations of half-lives and concomitant use. Neurotherapeutics. 2020;17:156–64.
doi: 10.1007/s13311-019-00801-9
Osler M, Jørgensen MB. Associations of benzodiazepines, Z-drugs, and other anxiolytics with subsequent dementia in patients with affective disorders: a nationwide cohort and nested case-control study. Am J Psychiatry. 2020;177:497–505.
Reyes AT, Constantino RE, Arenas RA, Bombard JN, Acupan AR. Exploring challenges in conducting E-mental health research among Asian American women. AsianPacific Isl Nurs J. 2018;3:139–53.
doi: 10.31372/20180304.1016
Quiroga C, Chaparro RE, Karlnoski R, Erasso D, Gordon M, Morgan D, et al. Effects of repetitive exposure to anesthetics and analgesics in the Tg2576 mouse Alzheimer’s model. Neurotox Res. 2014;26:414–21.
doi: 10.1007/s12640-014-9478-8
Tampellini D, Capetillo-Zarate E, Dumont M, Huang Z, Yu F, Lin MT, et al. Effects of synaptic modulation on -amyloid, synaptophysin, and memory performance in Alzheimer’s disease transgenic mice. J Neurosci. 2010;30:14299–304.
doi: 10.1523/JNEUROSCI.3383-10.2010
Yamamoto N, Arima H, Sugiura T, Hirate H, Kusama N, Suzuki K, et al. Midazolam inhibits the formation of amyloid fibrils and GM1 ganglioside-rich microdomains in presynaptic membranes through the gamma-aminobutyric acid A receptor. Biochem Biophys Res Commun. 2015;457:547–53.
doi: 10.1016/j.bbrc.2015.01.022
Chung JK, Nakajima S, Shinagawa S, Plitman E, Chakravarty MM, Iwata Y, et al. Benzodiazepine use attenuates cortical β-Amyloid and is not associated with progressive cognitive decline in nondemented elderly adults: a pilot study using F18-Florbetapir positron emission tomography. Am J Geriatr Psychiatry. 2016;24:1028–39.
doi: 10.1016/j.jagp.2016.04.013
Desmidt T, Delrieu J, Lebouvier T, Robert G, David R, Balageas AC, et al. Benzodiazepine use and brain amyloid load in nondemented older individuals: a florbetapir PET study in the Multidomain Alzheimer Preventive Trial cohort. Neurobiol. Aging. 2019;84:61–69.
doi: 10.1016/j.neurobiolaging.2019.08.008
Dufouil C, Dubois B, Vellas B, Pasquier F, Blanc F, Hugon J, et al. Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort. Alzheimers Res Ther. 2017;9:67.
doi: 10.1186/s13195-017-0288-0
Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in alzheimer disease using the radioligand
doi: 10.2967/jnumed.109.069088
Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol. 2012;11:669–78.
doi: 10.1016/S1474-4422(12)70142-4
Operto G, Chupin M, Batrancourt B, Habert MO, Colliot O, Benali H, et al. CATI: a large distributed infrastructure for the neuroimaging of cohorts. Neuroinformatics. 2016;14:253–64.
doi: 10.1007/s12021-016-9295-8
Habert M-O, Marie S, Bertin H, Reynal M, Martini JB, Diallo M, et al. Optimization of brain PET imaging for a multicentre trial: the French CATI experience. EJNMMI Phys. 2016;3:6.
doi: 10.1186/s40658-016-0141-8
Ashburner J, Friston KJ. Unified segmentation. Neuroimage. 2005;26:839–51.
doi: 10.1016/j.neuroimage.2005.02.018
Chupin M, Hammers A, Liu RSN, Colliot O, Burdett J, Bardinet E, et al. Automatic segmentation of the hippocampus and the amygdala driven by hybrid constraints: method and validation. Neuroimage. 2009;46:749–61.
doi: 10.1016/j.neuroimage.2009.02.013
Habert M-O, Bertin H, Labit M, Diallo M, Marie S, Martineau K, et al. Evaluation of amyloid status in a cohort of elderly individuals with memory complaints: validation of the method of quantification and determination of positivity thresholds. Ann Nucl Med. 2018;32:75–86.
doi: 10.1007/s12149-017-1221-0
Haider SI, Johnell K, Weitoft GR, Thorslund M, Fastbom J. The influence of educational level on polypharmacy and inappropriate drug use: a register-based study of more than 600,000 older people: polypharmacy and inappropriate drug use in the elderly. J Am Geriatr Soc. 2009;57:62–69.
doi: 10.1111/j.1532-5415.2008.02040.x
Crowe SF, Stranks E. Sci-Hub | The residual medium and long-term cognitive effects of benzodiazepine use: an updated meta-analysis. Arch Clin Neuropsychol. 2017. https://doi.org/10.1093/arclin/acx120 . https://sci-hubtw.hkvisa.net/ .
Conejero I, Dubois J, Gutierrez LA, Delrieu J, Arbus C, Garcia M, et al. Amyloid burden and depressive symptom trajectories in older adults at risk of developing cognitive decline. J Clin Psychiatry. 2021;82:20m13410.
doi: 10.4088/JCP.20m13410
Chen F, Bertelsen AB, Holm IE, Nyengaard JR, Rosenberg R, Dorph-Petersen KA. Hippocampal volume and cell number in depression, schizophrenia, and suicide subjects. Brain Res. 2020;1727:146546.
doi: 10.1016/j.brainres.2019.146546
Fouquet M, Besson FL, Gonneaud J, La Joie R, Chételat G. Imaging brain effects of APOE4 in cognitively normal individuals across the lifespan. Neuropsychol Rev. 2014;24:290–9.
doi: 10.1007/s11065-014-9263-8
Jack CR, Petersen RC, Xu YC, O'Brien PC, Waring SC, Tangalos EG, et al. Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer’s disease. Ann Neurol. 1998;43:303–10.
doi: 10.1002/ana.410430307
Operto G, Chupin M, Batrancourt B, Habert MO, Colliot O, Benali H, et al. CATI: a large distributed infrastructure for the neuroimaging of cohorts. Neuroinformatics. 2016;14:253–64.
doi: 10.1007/s12021-016-9295-8
Pilipenko V, Narbute K, Pupure J, Rumaks J, Jansone B, Klusa V. Neuroprotective action of diazepam at very low and moderate doses in Alzheimer’s disease model rats. Neuropharmacology. 2019;144:319–26.
doi: 10.1016/j.neuropharm.2018.11.003
Arbo BD, Marques CV, Ruiz-Palmero I, Ortiz-Rodriguez A, Ghorbanpoor S, Arevalo MA, et al. 4′-Chlorodiazepam is neuroprotective against amyloid-beta through the modulation of survivin and bax protein expression in vitro. Brain Res. 2016;1632:91–97.
doi: 10.1016/j.brainres.2015.12.018
Haberman RP, Branch A, Gallagher M. Targeting neural hyperactivity as a treatment to stem progression of late-onset Alzheimer’s disease. Neurotherapeutics. 2017;14:662–76.
doi: 10.1007/s13311-017-0541-z
Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, et al. Neuronal activity regulates the regional vulnerability to amyloid-β deposition. Nat Neurosci. 2011;14:750–6.
doi: 10.1038/nn.2801
Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, Silverio LM, et al. Endocytosis is required for synaptic activity-dependent release of amyloid-β in vivo. Neuron. 2008;58:42–51.
doi: 10.1016/j.neuron.2008.02.003
Busche MA, Konnerth A. Impairments of neural circuit function in Alzheimer’s disease. Philos Trans R Soc B Biol Sci. 2016;371:20150429.
doi: 10.1098/rstb.2015.0429
Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, et al. Synaptic activity regulates interstitial fluid amyloid-β levels in vivo. Neuron. 2005;48:913–22.
doi: 10.1016/j.neuron.2005.10.028
Yuan P, Grutzendler J. Attenuation of -amyloid deposition and neurotoxicity by chemogenetic modulation of neural activity. J Neurosci. 2016;36:632–41.
doi: 10.1523/JNEUROSCI.2531-15.2016
Veenman L, Papadopoulos V, Gavish M. Channel-Like Functions of the 18-kDa Translocator Protein (TSPO): regulation of apoptosis and steroidogenesis as part of the host-defense response. Curr Pharm Des. 2007;13:2385–405.
doi: 10.2174/138161207781368710
Arbo BD, Benetti F, Garcia-Segura LM, Ribeiro MF. Therapeutic actions of translocator protein (18 kDa) ligands in experimental models of psychiatric disorders and neurodegenerative diseases. J. Steroid Biochem Mol Biol. 2015;154:68–74.
doi: 10.1016/j.jsbmb.2015.07.007
Huhtaniska S, Korkala I, Heikka T, Björnholm L, Lehtiniemi H, Hulkko AP, et al. Antipsychotic and benzodiazepine use and brain morphology in schizophrenia and affective psychoses – Systematic reviews and birth cohort study. Psychiatry Res Neuroimaging. 2018;281:43–52.
doi: 10.1016/j.pscychresns.2018.08.015
Licata SC, Shinday NM, Huizenga MN, Darnell SB, Sangrey GR, Rudolph U, et al. Alterations in brain-derived neurotrophic factor in the mouse hippocampus following acute but not repeated benzodiazepine treatment. PLoS ONE. 2013;8:e84806.
doi: 10.1371/journal.pone.0084806
Jack CR Jr, Wiste HJ, Knopman DS, Vemuri P, Mielke MM, Weigand SD, et al. Rates of -amyloid accumulation are independent of hippocampal neurodegeneration. Neurology. 2014;82:1605–12.
doi: 10.1212/WNL.0000000000000386
Sperk G, Schwarzer C, Tsunashima K, Fuchs K, Sieghart W. GABAA receptor subunits in the rat hippocampus I: Immunocytochemical distribution of 13 subunits. Neuroscience. 1997;80:987–1000.
doi: 10.1016/S0306-4522(97)00146-2
Kreutzmann JC, Havekes R, Abel T, Meerlo P. Sleep deprivation and hippocampal vulnerability: changes in neuronal plasticity, neurogenesis and cognitive function. Neuroscience. 2015;309:173–90.
doi: 10.1016/j.neuroscience.2015.04.053